Results 11 to 20 of about 2,385 (197)

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry [PDF]

BMC Cardiovascular Disorders, 2021
Background Despite the advances of potent oral P2Y12 inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI).
A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides   +13 more
doaj   +2 more sources

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study [PDF]

Cardiology Research and Practice, 2023
Background. Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed. Objectives. To describe real-world use of cangrelor including patient
Troels Thim, Lars Jakobsen, Rebekka Vibjerg Jensen, Nicolaj Støttrup, Ashkan Eftekhari, Erik Lerkevang Grove, Sanne Bøjet Larsen, Jacob Thorsted Sørensen, Steen Carstensen, Sahar Amiri, Karsten Tange Veien, Evald Høj Christiansen, Christian Juhl Terkelsen, Michael Maeng, Steen Dalby Kristensen   +14 more
doaj   +2 more sources

Cangrelor — Expanding therapeutic options in patients with acute coronary syndrome [PDF]

Cardiology Journal
Cangrelor is the only intravenous P2Y12 receptor antagonist. It is an adenosine triphosphate analog that selectively, directly, and reversibly binds to the platelet P2Y12 receptors exerting its antiaggregatory effect. Cangrelor is characterized by linear,
Jacek Kubica, Piotr Adamski, Sławomir Dobrzycki, Robert Gajda, Mariusz Gąsior, Marek Gierlotka, Miłosz Jaguszewski, Jacek Legutko, Maciej Lesiak, Eliano P. Navarese, Piotr Niezgoda, Małgorzata Ostrowska, Tomasz Pawłowski, Agnieszka Tycińska, Julia M. Umińska, Adam Witkowski, Robert Gil   +16 more
doaj   +5 more sources

The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. [PDF]

PLoS ONE, 2012
ADP is an important physiological agonist that induces integrin activation and platelet aggregation through its receptors P2Y(1) (Gα(q)-coupled) and P2Y(12) (Gα(i)-coupled). P2Y(12) plays a critical role in platelet activation and thrombosis.
Binggang Xiang, Guoying Zhang, Hongmei Ren, Manjula Sunkara, Andrew J Morris, T Kent Gartner, Susan S Smyth, Zhenyu Li   +7 more
doaj   +4 more sources

Platelet Function Testing to Guide Cangrelor Dosing in Patients with Temporary Mechanical Circulatory Support or as a Bridge to Procedure [PDF]

Clinical and Applied Thrombosis/Hemostasis
Cangrelor is a rapid-acting, intravenous P2Y12 inhibitor that can be used in patients after percutaneous coronary intervention who require mechanical circulatory support or as a bridge to procedure. We retrospectively reviewed adult patients who received
Margaret M. Buck PharmD, Chelsea I. Barry PharmD, Courtney A. Montepara PharmD, Nathan J. Verlinden PharmD   +3 more
doaj   +2 more sources

Use of Cangrelor in Patients Undergoing Percutaneous Coronary Intervention: Insights and Outcomes from District General Hospital [PDF]

Hearts
Background/Objectives: Cangrelor, an intravenous P2Y12 inhibitor, is increasingly used during percutaneous coronary intervention (PCI) for rapid and reversible platelet inhibition in patients unable to take oral antiplatelet agents, particularly in ...
Ibrahim Antoun, Sotirios Dardas, Falik Sher, Mueed Akram, Navid Munir, Georgia R. Layton, Mustafa Zakkar, Kamal Chitkara, Riyaz Somani, Andre Ng   +9 more
doaj   +2 more sources

Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. Methods: The PharmacOdynaMic effects
Giuseppe Gargiulo, Plinio Cirillo, Luca Sperandeo, Imma Forzano, Domenico Simone Castiello, Domenico Florimonte, Fiorenzo Simonetti, Roberta Paolillo, Lina Manzi, Alessandra Spinelli, Carmen Anna Maria Spaccarotella, Raffaele Piccolo, Luigi Di Serafino, Anna Franzone, Piera Capranzano, Marco Valgimigli, Giovanni Esposito   +16 more
doaj   +3 more sources

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). [PDF]

, 2016
BACKGROUND: Cangrelor is an intravenous P2Y12 inhibitor approved to reduce periprocedural ischemic events in patients undergoing percutaneous coronary intervention not pretreated with a P2Y12 inhibitor. METHODS: A total of 11 145 patients were randomized
Steg, PG, Deliargyris, EN, CHAMPION PHOENIX Investigators*, Hamm, CW, Mahaffey, KW, Gibson, CM, Stone, GW, Price, MJ, Bhatt, DL, Leonardi, S, Harrington, RA, White, HD, Prats, J, Cavender, MA   +13 more
core   +8 more sources

Receptor-Dependent and -Independent Effects of Hemin on Platelet Plasma Membrane Disintegration. [PDF]

FASEB J
Microhemorrhages lead to the release of erythrocytes, which are then degraded and lysed. These hemolyses result in the liberation of free iron‐containing hemin. Hemin induces platelet activation and ferroptosis. Inhibition of GPVI/CLEC‐2 receptor‐mediated ITAM‐signaling inhibits hemin‐induced platelet activation (low hemin concentrations). Deferoxamine,
Laspa Z, Rohlfing AK, Hochuli R, Sowa PW, Castor T, Gawaz MP.   +5 more
europepmc   +2 more sources

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention [PDF]

, 2017
Background Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention (PCI).
Deliargyris, EN, Steg, PG, Hamm, CW, Mahaffey, KW, Vaduganathan, M, Gibson, CM, Stone, GW, Price, MJ, Elkin, S, Harrington, RA, White, HD, Prats, J, Jayasinghe, R, et al., Menozzi, A   +14 more
core   +5 more sources